CryoLife seeks Australian/Canadian approval:
This article was originally published in Clinica
CryoLife is seeking approval in Australia and Canada for its BioGlue surgical adhesive to be used as a vascular and pulmonary sealant. In Australia, the approval process could take up to nine months. However, while it is under review, the Australian Therapeutic Goods Administration has agreed to allow doctors to use the adhesive if they apply for an individual patient use. The Atlanta, Georgia-based company already markets the product in Europe for vascular surgical procedures and pulmonary applications.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.